ASCO GUIDELINES Bundle

Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475468

Contents of this Issue

Navigation

Page 53 of 71

54 Treatment Table 7. Nervous System Toxicities 7.7 Demyelinating diseases, including multiple sclerosis, transverse myelitis, acute-disseminated encephalomyelitis (ADEM), optic neuritis (ON) and neuromyelitis optica (NMO) Workup/Evaluation • Neurologic consultation. • Ophthalmic or neuro-ophthalmic evaluation if ocular involvement • MRI with contrast of brain, orbit, cervical, and thoracic spinal cord (tailor to exam finding ). • Lumbar puncture with CSF analysis including autoimmune encephalitis panel and oligoclonal bands, CNS demyelinating disease antibodies (aquaporin 4 and myelin oligodendrocyte glycoprotein), viral PCRs especially JCV PCR to exclude progressive multifocal leukoencephalopathy. • Serum studies: B12, HIV, rapid plasma reagin, ANA, Ro/La, TSH, aquaporin-4 immunoglobulin G (IgG), paraneoplastic panel or anti-HU and anti-CRMP5- CV2, thyroid panel including TPO and thyroglobulin, am cortisol and ACTH, paraneoplastic and autoimmune encephalitis panels. • Evaluation for urinary retention, constipation. • EEG to evaluate for subclinical seizures. • Although less common, biopsy may provide definitive evidence of CNS demyelination Grading Management G1: Asymptomatic or mild symptoms; clinical or diagnostic observations only • Intervention not indicated. • Continue immunotherapy unless symptoms worsen or do not improve. G2: Moderate symptoms; minimal, limiting age-appropriate instrumental ADL • Stop ICPi. • Neurolog y consultation. • Start prednisone 1 mg/kg daily and taper over 1 month. • Rule out infection. G3–4: Severe or medically significant symptoms but not immediately life-threatening ; limiting self-care ADL • Permanently discontinue ICPi. • Neurolog y consultation. • Non opioid management of neuropathic pain, for example, pregabalin, gabapentin, or duloxetine. • Admit patient for methylprednisolone pulse dosing 1g/day and consider IVIG* or plasmapheresis if no improvement or symptoms worsen after 3 days.** Footnotes: * IVIG 2 g/kg, administered in divided doses per package insert. ** Plasmapheresis immediately aer IVIG will remove immunoglobulin. (cont'd)

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy